CI-1011 lowers lipoprotein(a) and plasma cholesterol concentrations in chow-fed cynomolgus monkeys

Atherosclerosis
R RamharackB R Krause

Abstract

Lipoprotein(a) (Lp(a)), which is generated through the covalent association of apolipoprotein(a) (apo(a)) and apo B-100-LDL, is an independent risk factor for several vascular diseases. Therefore, there is interest in developing therapies for lowering Lp(a). This investigation was carried out to determine the effect of CI-1011, a potent lipid regulator in rodents, on Lp(a) and other lipid parameters in cynomolgus monkeys (Macaca fascicularis). Nine healthy male monkeys on a normal chow diet were orally treated with CI-1011 at 30 mg/kg per day for 3 weeks. Lp(a) and total cholesterol levels were significantly decreased after 1 week and maximally reduced to 68 and 73% of control levels, respectively, after 3 treatment weeks. The decreases in total cholesterol were mainly due to changes in low density lipoprotein (LDL). The LDL:HDL ratio decreased by 30%. Triglycerides were unaffected by treatment. Lp(a) and total cholesterol levels returned to pretreatment values after stopping treatment suggesting a direct effect of the compound on their inhibition. Further studies demonstrated that CI-1011 was effective at a low dose of 3 mg/kg per day after 1 week of administration. CI-1011 also decreased apo B-100 to 80% of control levels, bu...Continue Reading

References

Oct 1, 1992·Journal of Internal Medicine·J TyrrellJ Feely
Jan 1, 1992·Atherosclerosis·D CrookJ C Stevenson
Aug 1, 1992·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·J MölgaardA G Olsson
Sep 1, 1991·Lipids·K Makino, A M Scanu
Nov 17, 1989·Science·G Utermann
Nov 1, 1985·Atherosclerosis·A GurakarH B Brewer
Sep 1, 1986·Stroke; a Journal of Cerebral Circulation·G ZenkerG Jürgens
Jul 1, 1988·Arteriosclerosis : an Official Journal of the American Heart Association, Inc·G HoeflerG M Kostner
Oct 1, 1994·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·D A ShewmonS Baker
Jan 1, 1995·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·I C KlausenO Faergeman
May 1, 1995·Atherosclerosis·F HoppichlerH G Kraft
Apr 6, 1994·JAMA : the Journal of the American Medical Association·E J SchaeferR I Levy
May 23, 1994·Archives of Internal Medicine·F M SacksB W Walsh
Apr 1, 1993·Atherosclerosis·F M MaggiA L Catapano
Jun 1, 1996·The American Journal of Cardiology·J M ZmundaL L Bausserman
Jul 1, 1996·The Journal of Clinical Endocrinology and Metabolism·L BerglundP Henriksson
Aug 21, 1996·JAMA : the Journal of the American Medical Association·A G BostomW P Castelli
Dec 1, 1996·Obstetrics and Gynecology·F BruschiP G Crosignani
Jan 21, 1997·Circulation·K Orth-GomérL Rydén

❮ Previous
Next ❯

Citations

Jul 27, 1999·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·S M PostH M Princen
Jul 13, 2006·Current Opinion in Lipidology·Marijn C MeuweseJohn J P Kastelein
Oct 25, 2002·Drugs·Thomas Sudhop, Klaus von Bergmann
Nov 22, 2011·Future Medicinal Chemistry·Taichi Ohshiro, Hiroshi Tomoda
Oct 8, 1999·Clinica Chimica Acta; International Journal of Clinical Chemistry·J R BurnettM W Huff
Oct 31, 2003·Expert Opinion on Investigational Drugs·Pedro Iglesias, Juan J Díez
Jul 5, 2005·Expert Opinion on Investigational Drugs·P Duriez, J C Fruchart
Mar 12, 2003·Critical Reviews in Clinical Laboratory Sciences·Giuseppe Lippi, Giancesare Guidi

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.